Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma

doi:10.5306/wjco.v4.i2.29

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 2

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5296)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-4) series.

Item

Count

PDF

463

HTML

2828

Tables (1-4)

159

Sum=3450

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

980

Download

866

Sum=1846

May 10, 2013 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. May 10, 2013; 4(2): 29-42
Published online May 10, 2013. doi: 10.5306/wjco.v4.i2.29

Table 3 Major ongoing clinical trials with crizotinib for advanced non-small cell lung cancer¹

Trial number	Phase	Study design	Key entry criteria	PE
PROFILE 1007 (NCT00932893)	III	Crizotinib vs Pem or Doc as second-line	ALK(+) and 1 prior platinum-based chemo	PFS
PROFILE 1014 (NCT01154140)	III	Crizotinib + Pem + Cis/Carbo vs Pem + Cis/Carbo as first-line	ALK(+) and chemotherapy-naive	PFS
PROFILE 1005 (NCT00932451)	II	Crizotinib vs placebo as third-line	ALK(+) and PD in arm B of study PROFILE 1007	RR
PROFILE 1001 (NCT00965731)	I/II	Crizotinib + erlotinib vs erlotinib as second or third-line	Adenocarcinoma NSCLC and 1-2 prior chemo	MTD
PROFILE 1001 (NCT01121575)	I	Crizotinib + PF0299804	Acquired resistance to erlotinib or gefitinib	MTD

¹Data available at URL: http://www.cancer.gov/clinicaltrials. chemo: Chemotherapy; Pem: Pemetrexed; Doc: Docetaxel; Cis: Cisplatin; Carbo: Carboplatin; PD: Progressive disease; NSCLC: Non-small cell lung cancer; ALK: Anaplastic lymphoma kinase; PFS: Progression-free survival; RR: Response rate; MTD: Maximum tolerated dose; PE: Primary endpoint.

Citation: Bayraktar S, Rocha-Lima CM. Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. World J Clin Oncol 2013; 4(2): 29-42
URL: https://www.wjgnet.com/2218-4333/full/v4/i2/29.htm
DOI: https://dx.doi.org/10.5306/wjco.v4.i2.29